Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of MK-4082 With and Without Diltiazem in Healthy Participants
NCT07697625Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2026
- Primary completion
- Oct 2026
- Countries
- 1
01
Overview
Phase 1, randomised trial of HS-10535 in obesity, sponsored by Merck & Co. Primary endpoints: Area Under the Concentration-Time Curve From Time 0 to Infinity up to 1 week, Maximum Plasma Concentration up to 1 week and 2 more. Started Jul 2026; status: completed.
02
Drugs
HS-10535
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07697625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07697625.